Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Amy Elazzouzi reported a sale of 1,581 shares of Common Stock on 01/20/2026. The filing shows Restricted Stock Unit awards of 4,583 granted 02/01/2024 and 11,310 granted 02/03/2025, each described as subject to vesting under the 2021 Stock Option and Incentive Plan.
The broker listed is Morgan Stanley Smith Barney LLC at the address shown, and the filing references Nasdaq with an apparent filing activity date of 02/17/2026.
Aura Biosciences filed a Form 144 reporting a proposed sale of 47,648 shares of Common Stock. The filing lists Morgan Stanley Smith Barney LLC as the broker and Nasdaq as the market. The filing also shows prior insider activity: Elisabet de los Pinos sold 16,928 shares on 01/20/2026 for $82,234.36.
Kilroy Conor reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 12,079 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 167,234 shares.
Plavsic Mark reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 15,890 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 181,397 shares.
Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 20,401 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 232,284 shares.
Elazzouzi Amy reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 8,549 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 75,532 shares.
de los Pinos Elisabet reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 47,648 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 409,815 shares.
Aura Biosciences, Inc. received an updated Schedule 13G/A from a group of Frazier Life Sciences funds and related entities reporting passive ownership of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 4,032,060 shares of Aura common stock, representing 6.3% of the class based on 63,503,269 shares outstanding as of November 10, 2025. Other affiliated Frazier funds directly hold additional stakes of 128,520 shares (0.2%), 342,210 shares (0.5%), and 597,210 shares (0.9%), with voting and investment power allocated through various Delaware limited partnerships and limited liability companies.
The filing notes that these ownership figures exclude prefunded warrants. The funds hold warrants to purchase 1,008,016, 32,130, 85,552, and 149,302 additional shares of common stock, each subject to a 9.99% beneficial ownership limitation, which prevents exercise if it would push the holder above that ownership threshold. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Aura Biosciences.
Aura Biosciences insider Amy Elazzouzi has filed a Form 144 indicating an intention to sell up to 1,581 shares of the company’s common stock through broker Morgan Stanley Smith Barney LLC on or about 01/20/2026. The filing lists an aggregate market value of $7,683.66 for this planned sale, with 63,503,269 shares of common stock outstanding and the stock listed on Nasdaq.
The securities to be sold were originally acquired as a restricted stock unit award granted on 01/19/2023 under Aura Biosciences’ 2021 Stock Option and Incentive Plan, in an amount of 2,844 shares. Over the past three months, the same seller has sold 896 shares of common stock for gross proceeds of $5,689.60. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Aura Biosciences.
Aura Biosciences insider Elisabet de los Pinos has filed a Rule 144 notice to sell 16,928 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an indicated aggregate market value of $82,234.36 on Nasdaq. These shares relate to a restricted stock unit award of 30,469 shares granted on 01/19/2023 under the company’s 2021 Stock Option and Incentive Plan. The notice also discloses that 9,049 shares of common stock were sold in the past three months for $57,461.15. Aura Biosciences had 63,503,269 shares of common stock outstanding, providing scale for the planned sale.